TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12011283
Drug: Anti-NF-L antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-NF-L antibodies in PPMS and SPMS
Study: 12011283
Drug: Anti-NF-L antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-NF-L antibodies
Study: 7710795
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a small amount of contrast medium rapidly via the antecubital vein and measurement of aortic transit time (ATT) by single slice dynamic CT.
Study: 7710795
Drug: Spiral scanning
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiral scanning of the liver using thin collimation and caudo-cranial table movement beginning at ATT after the end of contrast medium injection.
Study: 2838426
Drug: Oral iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iodized oil (2 ml)
Study: 2838426
Drug: Intramuscular iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iodized oil (2 ml)
Study: 407559
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate (BV, 800 microgram daily)
Study: 407559
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG, 80 mg daily)
Study: 29679637
Drug: Non-reactive stimulant
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-reactive stimulant users (n=28)
Study: 28271623
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule (BIO-25), twice daily for 8 weeks
Study: 25681139
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment with thiazides, alpha-methyldopa, and propranolol; n = 406
Study: 18446389
Drug: Scaling, root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling, root planning, and chlorhexidine rinses for 3 months with systemic administration of doxycycline (100 mg once a day for 15 days)
Study: 18446389
Drug: Scaling, root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling, root planning, and chlorhexidine rinses for 3 months without systemic administration of doxycycline
Study: 16531178
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by vaginal misoprostol 800 mcg after 6-8 hours
Study: 16531178
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by vaginal misoprostol 800 mcg after 24 hours
Study: 21881569
Drug: Spironolactone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (400 mg)
Study: 23303058
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg at 2300 hours)
Study: 21112791
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MGSS and clinical palpation
Study: 6138060
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg midazolam
Study: 6138063
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg midazolam
Study: 6138063
Drug: Midazolam (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (10, 20, 30 mg)
Study: 3718586
Drug: Brotizolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam (0.25 mg)
Study: 21463150
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus CABG
Study: 21463153
Drug: Treatment assignment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assignment
Study: 9190629
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (low dose)
Study: 2936564
Drug: Nafarelin acetate
Normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafarelin acetate 125 micrograms daily
Study: 2936564
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of nafarelin acetate
Study: 17135988
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management with pill placebo
Study: 14514569
Drug: Pravastatin therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy, 40 mg/day over 6.0 years
Study: 9285143
Drug: Urinary IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary IgG excretion
Study: 9285143
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum albumin and transferrin, high urinary transferrin, beta-microglobulin, and IgG excretion
Study: 8360131
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg/day given as a single dose (once-daily)
Study: 8360131
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg/day given in two divided doses at 12 h intervals (twice-daily)
Study: 3526986
Drug: one inhalation
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one inhalation isoetharine mesylate (IM)
Study: 3526986
Drug: one inhalation
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one inhalation placebo (P)
Study: 26837471
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell‐based inactivated EV71 vaccine
Study: 17313873
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg daily for at least 52 weeks
Study: 17313873
Drug: Lamivudine (LVD)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LVD) 100 mg daily for at least 52 weeks
Study: 12505243
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group
Study: 8590144
Drug: H. pylori-positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori-positive after treatment
Study: 2665761
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decolonization (SDD) with non-resorbable antibiotics: 4 x 100 mg of polymyxin B, 4 x 500 mg of amphotericin B, and 4 x 80 mg of tobramycin via gastric tube.
Study: 2665761
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decolonization (SDD) with non-resorbable antibiotics.
Study: 2665761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SDD treatment).
Study: 21886949
Drug: Upper Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper Body Resistance Training (UBRT) for 4 weeks, 3 times weekly
Study: 14750577
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/day for 16 weeks)
Study: 26741286
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) administration (40 IU)
Study: 25421781
Drug: Telephone-delivered physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered physical activity intervention (pedometers and eight weekly phone calls)
Study: 18823000
Drug: Web-based, self-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based, self-guided alcohol treatment program
Study: 10418756
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (STD)
Study: 27136447
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and acupuncture combined therapy
Study: 25174484
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mannitol
Study: 19952822
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg x kg(−1) caffeine
Study: 19952822
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg x kg(−1) caffeine
Study: 9920950
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiotherapy (45 Gy over three weeks)
Study: 9920950
Drug: Once-daily thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily thoracic radiotherapy (45 Gy over five weeks)
Study: 9920950
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic radiotherapy
Study: 9920950
Drug: Once-daily thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily thoracic radiotherapy
Study: 7731455
Drug: Intraportal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraportal infusion of 5-fluorouracil (500mg per day) for 14 days from 21 postoperative days and lipiodol-aclarubicin (40mg) at 35 POD
Study: 7731455
Drug: Intraportal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraportal infusion of 5-fluorouracil and lipiodol-aclarubicin
Study: 1665176
Drug: Lisinopril-Hydrochlorothiazide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril-Hydrochlorothiazide 20 mg/12.5 mg
Study: 1665176
Drug: Lisinopril-Hydrochlorothiazide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril-Hydrochlorothiazide 20 mg/25 mg
Study: 7789045
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg
Study: 7927956
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg
Study: 7378250
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion intravenously at different rates
Study: 24768290
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (30 mg)
Study: 26193882
Drug: Individualised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised physical activity on prescription (PAP) for 6 months
Study: 20212249
Drug: DD (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DD (both doses)
Study: 18035198
Drug: Fluvastatin (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20, 40, and 80 mg daily)
Study: 15727648
Drug: Altoderm lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altoderm lotion
Study: 9840118
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic acid (500 mg or 750 mg daily for 6 months)
Study: 8302553
Drug: Fluorescein solution
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescein solution (5 microliters) administered under the upper lid
Study: 8302553
Drug: Fluorescein solution
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescein solution (5 microliters) administered under the lower lid
Study: 9554429
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/d)
Study: 29189044
Drug: Desvenlafaxine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (25-50 mg/d)
Study: 24761877
Drug: Glycididazole sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycididazole sodium (CMNa) 800 mg/m2 before radiotherapy, administered by intravenous drip, three times a week
Study: 8752611
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel)
Study: 8752611
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral contraceptive therapy
Study: 8752611
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a, leuprolide acetate depot 3.75 mg)
Study: 8752611
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive therapy
Study: 1790313
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation administered with water or milk
Study: 29560937
Drug: Submaximal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submaximal doses of mexidol (750 mg infusion in 250 ml of 0.9% NaCl solution for 6 days)
Study: 27129606
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam
Study: 11576093
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg x kg(‐1)
Study: 7711149
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition guideline involving a commercialized enteral diet administered in 6 sessions at three-hour intervals, starting with 100 cc per session up to a total of 400 cc (2400 kcal/day) with 100 cc of water added.
Study: 2523656
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 to 20 mg twice daily
Study: 2894890
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 to 100 mg once daily
Study: 826948
Drug: Nootropyl (Piracetam)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropyl (Piracetam) 400 mg per day for 14 days
Study: 26975498
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula oxygen therapy
Study: 20632888
Drug: 5-microg whole-virion
Normalized name: Acetosella acetosella whole
DrugBank: Rumex acetosella whole (DB14166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-microg whole-virion aluminum formulation
Study: 20632888
Drug: 30-microg split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-microg split-virion nonaluminum formulation
Study: 20632888
Drug: 15-microg split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-microg split-virion formulation
Study: 27801706
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT)
Study: 14687955
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous depot injection of 58 mg buprenorphine
Study: 15197803
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (HDM)
Study: 31703653
Drug: High birth
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High birth weight (BW ≥ 3500 g)
Study: 25961283
Drug: Ad35-GRIN followed
Normalized name: GRINDELIA CILIATA POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35-GRIN followed by two doses of F4/AS01B
Study: 25961283
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of an adjuvanted protein and an adenovirus vector
Study: 16420273
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (pseudo-application)
Study: 9394367
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (general)
Study: 20107214
Drug: Pooled vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled vaccine group (two or three doses of vaccine)
Study: 20107214
Drug: Pooled vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled vaccine group
Study: 22677305
Drug: Diclofenac-K 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-K 12.5 mg tablets
Study: 20541301
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg orally, 4 doses at 12-hour intervals
Study: 15565899
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin treatment
Study: 30591656
Drug: Preventive Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Zinc (PZ) tablets (7 mg/day)
Study: 30591656
Drug: Therapeutic Zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Study: 30591656
Drug: Multiple Micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Micronutrient Powder (MNP) sachets (10 mg zinc and 14 other micronutrients)
Study: 27574788
Drug: AZD5069 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 5 mg
Study: 27574788
Drug: AZD5069 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 15 mg
Study: 25201763
Drug: Frequent skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent skin care (oil bath (0.5 dl) and facial fat cream)
Study: 25471197
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg caffeine
Study: 19200991
Drug: 75 IU
Normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU of rLH daily for 4 days
Study: 10390007
Drug: ECF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECF regimen (epirubicin, cisplatin, and protracted venous infusion fluorouracil)
Study: 8430924
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 300 micrograms daily
Study: 29763659
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 160/14.4/10 μg
Study: 9359442
Drug: Anti-inflammatory therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory therapy
Study: 8942455
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group therapy
Study: 17295570
Drug: Interpretive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpretive group therapy
Study: 25736422
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy
Study: 8877209
Drug: Adenoidectomy (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoidectomy (in combination with other minor procedures)
Study: 27227692
Drug: Pain Coping
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Coping Skills Training (cognitive behavioral therapy)
Study: 24497963
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d added to interferon beta-1b (IFNB-1b)
Study: 24497963
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFNB-1b) monotherapy
Study: 1781761
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate cream 0.1% applied once daily
Study: 10489492
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream 0.05% applied twice daily
Study: 1874210
Drug: Etomidate 1
Normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 1 mg kg‐1 followed by 1 mg kg‐1 h‐1
Study: 1874210
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg‐1 followed by 9 mg kg‐1 h‐1
Study: 23241930
Drug: Meriva® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meriva® (2 tablets/day, each containing 500 mg Meriva® corresponding to 100 mg curcumin) for at least 4 weeks
Study: 10437219
Drug: Propafenone (Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (Western drug)
Study: 7850847
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by 0.4% stannous fluoride (SnF2) gel for 14 days
Study: 30312595
Drug: Patient-centered graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered graded exposure intervention added to manual therapy
Study: 28383927
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities writing (writing objectively about daily activities)
Study: 21190917
Drug: Test Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test Clarithromycin tablets 500 mg
Study: 21190917
Drug: Reference Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference Clarithromycin tablets 500 mg
Study: 18501094
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies (e.g., cetuximab, bevacizumab)
Study: 8848912
Drug: Doxapram 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 0.5 mg.kg-1
Study: 8848912
Drug: Doxapram 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 0.5 mg.kg-1 with alfentanil pre-treatment
Study: 28953856
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (0, 1, or 2 mg/kg/day) from 6 weeks to 6 months of age
Study: 28953856
Drug: Combined supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplemented groups (1 or 2 mg/kg/day)